{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:16Z","timestamp":1792088176094,"version":"4.4.0"},"reference-count":49,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Metformin (MTF) is a widely used drug for the treatment of diabetes mellitus type 2 (DM2) and frequently used as an adjuvant therapy for polycystic ovarian syndrome, metabolic syndrome, and in some cases also tuberculosis. Its protective effect on the cardiovascular system has also been described. Recently, MTF was subjected to various analyzes and studies that showed its beneficial effects in cancer treatment such as reducing cancer cell proliferation, reducing tumor growth, inducing apoptosis, reducing cancer risk in diabetic patients, or reducing likelihood of relapse. One of the MTF\u2019s mechanisms of action is the activation of adenosine-monophosphate-activated protein kinase (AMPK). Several studies have shown that AMPK\/mammalian target of rapamycin (mTOR) pathway has anticancer effect in vivo and in vitro. The aim of this review is to present the anticancer activity of MTF highlighting the importance of the AMPK\/mTOR pathway in the cancer process.<\/jats:p>","DOI":"10.33549\/physiolres.934618","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:14:45Z","timestamp":1630581285000},"page":"501-508","source":"Crossref","is-referenced-by-count":65,"title":["The Role of AMPK\/mTOR Signaling Pathway in Anticancer Activity of Metformin"],"prefix":"10.33549","author":[{"given":"Nikola","family":"Chomanicova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gazova","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Comenius University, Bratislava, Slovakia. andrea.gazova@fmed.uniba.sk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Adamickova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Valaskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kyselovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"ABDEL-WAHAB AF, MAHMOUD W, AL-HARIZY R: Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res 150: 104511, 2019. https:\/\/doi.org\/10.1016\/j.phrs.2019.104511","DOI":"10.1016\/j.phrs.2019.104511"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"BLOCK KI, GYLLENHAAL C, LOWE L, AMEDEI A, AMIN ARMR, AMIN A, AQUILANO K, ARBISER J, ARREOLA A, ARZUMANYAN A, et al: Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 35: 276-304, 2015. https:\/\/doi.org\/10.1016\/j.semcancer.2015.09.007","DOI":"10.1016\/j.semcancer.2015.09.007"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"CANTORIA MJ, PATEL H, BOROS LG, MEUILLET EJ: Metformin and pancreatic cancer metabolism. Pancreatic cancer-insights into molecular mechanisms and novel approaches to early detection and treatment. London, UK: IntechOpen, 2014. https:\/\/doi.org\/10.5772\/57432","DOI":"10.5772\/57432"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"CICCARESE F, ZULATO E, INDRACCOLO S: LKB1\/AMPK Pathway and drug response in cancer: A therapeutic perspective. Oxid Med Cell Longev: 8730816, 2019. https:\/\/doi.org\/10.1155\/2019\/8730816","DOI":"10.1155\/2019\/8730816"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"DELHALLE S, DUVOIX A, SCHNEKENBURGER M, MORCEAU F, DICATO M, DIEDERICH M: An introduction to the molecular mechanisms of apoptosis. Ann NY Acad Sci 1010: 1-8, 2003. https:\/\/doi.org\/10.1196\/annals.1299.001","DOI":"10.1196\/annals.1299.001"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"DI PIETRO M, VELAZQUES C, MATZKIN ME, FRUNGIERI MB, PENA MG, ZUNIGA I, PASCUALI N, IRUSTA G, BIANCHI MS, PARBORELL F, DALHIA A: Metformin has a direct effect on ovarian cells that is dependent on organic cation transporters. Mol Cell Endocrinol 499: 110591, 2020. https:\/\/doi.org\/10.1016\/j.mce.2019.110591","DOI":"10.1016\/j.mce.2019.110591"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"DZUIBAK A, WOJCICKA G, WOJTAK A, BELTOWSKI J: Metabolic effect of metformin in the failing heart. Int J Mol Sci 19: 2869, 2018. https:\/\/doi.org\/10.3390\/ijms19102869","DOI":"10.3390\/ijms19102869"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"EFFEYAN A, SABATINI DM: mTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol 22: 169-176, 2010. https:\/\/doi.org\/10.1016\/j.ceb.2009.10.007","DOI":"10.1016\/j.ceb.2009.10.007"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"FAN H, YU X, ZOU Z, ZHENG W, DENG X, GUO L, JIANG W, ZHAN Q, LU S-H: Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK\/mTOR signaling pathway. Carcinogenesis 40: 669-679, 2019. https:\/\/doi.org\/10.1093\/carcin\/bgy160","DOI":"10.1093\/carcin\/bgy160"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"FLORY JH, HENNESSY S, BAILEY CJ, INZUCCHI SE: Reports of actic acidosis attributed to metformin, 2015-2018. Diabetes Care 43: 244-246, 2020. https:\/\/doi.org\/10.2337\/dc19-0923","DOI":"10.2337\/dc19-0923"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"FORETZ M, GUIGAS B, BERTRAND L, POLLAK M, VIOLLET B: Metformin from mechanism of action to therapies. Cell Metab 20: 953-966, 2014. https:\/\/doi.org\/10.1016\/j.cmet.2014.09.018","DOI":"10.1016\/j.cmet.2014.09.018"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"FU P, CHEN F, PAN Q, ZHAO X, ZHAO C, CHO WC, CHEN H: The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma. Onco Targets and Therapy 10: 819-835, 2017. https:\/\/doi.org\/10.2147\/OTT.S123912","DOI":"10.2147\/ott.s123912"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"GALDIERI L, GATLA H, VANCUROVA I, VANCURA A: Activation of AMP-activated protein kinase by metformin induces protein acetylation in prostate and ovarian cancer cells. J Biol Chem 291: 25154-25166, 2016. https:\/\/doi.org\/10.1074\/jbc.M116.742247","DOI":"10.1074\/jbc.m116.742247"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"GAO ZY, LIU Z, BI MH, ZHANG JJ, HAN ZQ, HAN X, WANG HY, SUN GP, LIU H: Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Exp Ther Med 11: 1700-1706, 2016. https:\/\/doi.org\/10.3892\/etm.2016.3143","DOI":"10.3892\/etm.2016.3143"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"GWINN DM, SHACKELFORD DB, EGAN DF, MIHAYLOVA MM, MERY A, VASQUEZ DS, TURK BE, SHAW RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226, 2008. https:\/\/doi.org\/10.1016\/j.molcel.2008.03.003","DOI":"10.1016\/j.molcel.2008.03.003"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"HARDIE DG, HAWLEY SA: AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 23: 1112-1119, 2001. https:\/\/doi.org\/10.1002\/bies.10009","DOI":"10.1002\/bies.10009"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"HARDIE DG, ROSS FA, HAWLEY SA: AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13: 251-262, 2012. https:\/\/doi.org\/10.1038\/nrm3311","DOI":"10.1038\/nrm3311"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"HOWELL JJ, HELLBERG K, TURNER M, TALBITT G, KOLAR MJ, ROSS DV, HOXHAJ G, SAGHATELIAN A, SHAW RJ, MANNING BD: Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab 25: 463-471, 2017. https:\/\/doi.org\/10.1016\/j.cmet.2016.12.009","DOI":"10.1016\/j.cmet.2016.12.009"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"CHEN K, LI Y, GUO Z, ZENG Y, ZHANG W, WANG H: Metformin: current clinical applications in nondiabetic patients with cancer. Aging (Albany NY) 12: 3993-4009, 2020. https:\/\/doi.org\/10.18632\/aging.102787","DOI":"10.18632\/aging.102787"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"JACKULIAK P, KUZMA M, PAYER J: Effect of antidiabetic treatment on bone. Physiol Res 68 (Suppl 2): 107-120, 2019. https:\/\/doi.org\/10.33549\/physiolres.934297","DOI":"10.33549\/physiolres.934297"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"JEON S: Regulation and function of AMPK in physiology and diseases. Exp Mol Med 48: e245, 2016. https:\/\/doi.org\/10.1038\/emm.2016.81","DOI":"10.1038\/emm.2016.81"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"JIA J, BISSA B, BRECHT L, ALLERS L, CHOI SW, GU Y, ZBINDEN M, BURGE MR, TIMMINS G, HALLOWS K, BEHRENDS CH, DERETIC V: AMPK, a regulator of metabolism and autophagy, is activated by lysosomal damage via a novel galectin-directed ubiquitin signal transduction system. Mol Cell 77: 1-19, 2020. https:\/\/doi.org\/10.1016\/j.molcel.2019.12.028","DOI":"10.1016\/j.molcel.2019.12.028"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"KIM WJ: Is 5'-AMP-activated protein kinase both Jekyll and Hyde in bladder cancer? Int neurourol J 19: 55-66, 2015. https:\/\/doi.org\/10.5213\/inj.2015.19.2.55","DOI":"10.5213\/inj.2015.19.2.55"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"KNUDSON CM, KORSMEYER SJ: Bcl-2 and Bax function independenty to regulate cell death. Nat Gen 16: 358-363, 1997. https:\/\/doi.org\/10.1038\/ng0897-358","DOI":"10.1038\/ng0897-358"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"LEE J, HONG EM, KIM JH, PARK SW, KOH DH, CHOI MH, JANG HJ, KAE SH: Metformin induces apoptosis and inhibits proliferation through the AMP-activated protein kinase and insulin-like growth facror 1 receptor pathways in the bile duct cancer cells. J Cancer 10: 1734-1744, 2019. https:\/\/doi.org\/10.7150\/jca.26380","DOI":"10.7150\/jca.26380"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"LYONS C.L, ROCHE H. M: Nutritional modulation of AMPK-impact upon metabolic-inflammation. Int J Mol Sci 19: 3092, 2018. https:\/\/doi.org\/10.3390\/ijms19103092","DOI":"10.3390\/ijms19103092"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"MASCARAQUE M, DELGADO-WICKE P, NUEVO-TAPIOLES C, GRACIA-CAZANA T, ABARCA-LACHEN E, GONZALES S, CUEZVA JM, GILABERTE Y, JUARRANZ A: Metformin as an adjuvant to photodynamic therapy in resistant basal cell carcinoma cells. Cancers (Basel) 12: 668, 2020. https:\/\/doi.org\/10.3390\/cancers12030668","DOI":"10.3390\/cancers12030668"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"MOSCHETTA MG, LEONEL C, MASCHIO-SIGNORINI LB, BORIN TF, GELALETI GB, JARDIM-PERASSI BV, FERREIRA LC, SONEHARA NM, CARVALHO LGS, HELLMEN E, CAMPOS ZUCCARI D: Evaluation of angiogenesis process after metformin and LY294002 treatment in mammary tumor. Anticancer Agents Med Chem 19: 655-666, 2019. https:\/\/doi.org\/10.2174\/1871520619666181218164050","DOI":"10.2174\/1871520619666181218164050"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"PODHORECKA M, IBANEZ B, DMOSZYNSKA A: Metformin - its potential anti-cancer and anti-aging effects. Postepy Hig Med Dosw 71: 170-175, 2017. https:\/\/doi.org\/10.5604\/01.3001.0010.3801","DOI":"10.5604\/01.3001.0010.3801"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"RENA G, HARDIE DG, PEARSON E: The mechanisms of action of metformin. Diabetologia 60: 1577-1585, 2017. https:\/\/doi.org\/10.1007\/s00125-017-4342-z","DOI":"10.1007\/s00125-017-4342-z"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"SANLI T, STEINBERG GR, SINGH G, TSAKIRIDIS T. AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther 15: 156-169, 2014. https:\/\/doi.org\/10.4161\/cbt.26726","DOI":"10.4161\/cbt.26726"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"SAXTON RA, SABATINI DM: mTOR signaling in growth, metabolism, and disease. Cell 168: 960-976, 2017. https:\/\/doi.org\/10.1016\/j.cell.2017.02.004","DOI":"10.1016\/j.cell.2017.02.004"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"SARAEI P, ASADI I, KAKAR M A, MORADI-KOR N: The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res 11: 3295-3313, 2019. https:\/\/doi.org\/10.2147\/CMAR.S200059","DOI":"10.2147\/cmar.s200059"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"SCHNEIDER MB, MATSUZAKI H, HAORAH J, ULRICH A, STANDOP J, DING XZ, ADRIAN TE, POUR PM: Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterol 120: 1263-1270, 2001. https:\/\/doi.org\/10.1053\/gast.2001.23258","DOI":"10.1053\/gast.2001.23258"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"STAGE TB, BROSEN K, CHRISTENSEN MM: A comprehensive review of drug-drug interactions with metformin. Clin Pharmacokinet 54: 811-824, 2015. https:\/\/doi.org\/10.1007\/s40262-015-0270-6","DOI":"10.1007\/s40262-015-0270-6"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"TADAKAWA M, TAKEDA T, LI B, et al: The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1\/hypoxia-inducible factor-1\u03b1 signaling path-way in ELT-3 cells. Mol Cell Endocrinol 399: 1-8, 2015. https:\/\/doi.org\/10.1016\/j.mce.2014.08.012","DOI":"10.1016\/j.mce.2014.08.012"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"TONINI T, ROSSI F, CLAUDIO P: Molecular basis of angiogenesis and cancer. Oncogene 22: 6549-6556, 2003. https:\/\/doi.org\/10.1038\/sj.onc.1206816","DOI":"10.1038\/sj.onc.1206816"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"VACANTE F, SENESI P, MONTESANO A, PAINI S, LUZI L, TERRUZZI I: Metformin counteracts HCC progression and metastasis enhancing KLF6\/p21 expression and downregulating the IGF axis. Int J Endocrinol 2019: 7570146, 2019. https:\/\/doi.org\/10.1155\/2019\/7570146","DOI":"10.1155\/2019\/7570146"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"VARA-CIRUELOS D, DANDAPANI M, RUSSELL FM, GRZES KM, ATRIH A, FORETZ M, VIOLLET B, LAMONT DJ, CANTRELL DA, HARDIE DG: Phenformin, But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia\/Lymphoma via Cell-Autonomous AMPK Activation. Cell Rep 27: 690-698, 2019. https:\/\/doi.org\/10.1016\/j.celrep.2019.03.067","DOI":"10.1016\/j.celrep.2019.03.067"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"VOGELSTEIN B, PAPADOUPOULOS N, VELCULESCU VE, SHOU S, DIAZ LA Jr, KINZLER KW: Cancer genome landscapes. Science 339: 1546-1558, 2013. https:\/\/doi.org\/10.1126\/science.1235122","DOI":"10.1126\/science.1235122"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"WHITBURN J, EDWARDS CM, SOORIAKUMARAN P: Metformin and prostate cancer: a new role for an old drug. Curr Urol Rep 18: 46, 2017. https:\/\/doi.org\/10.1007\/s11934-017-0693-8","DOI":"10.1007\/s11934-017-0693-8"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"XIONG ZS, GING SF, SI W, JIANG T, LI QL, WANG TJ, WU RY, JIANG K: Effect of metformin on cell proliferation, apoptosis, migration and invasion in A172 glioma cells and its mechanisms. Mol Med Rep 20: 887-894, 2019. https:\/\/doi.org\/10.3892\/mmr.2019.10369","DOI":"10.3892\/mmr.2019.10369"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"YAMASHITA T, KATO K, FUJIHARA S, IWAMA H, MORISHITA A, YAMANA H, KOBAYASHI K, KAMADA H, CHIYO T, KOBARA H, TSUTSUI K, OKANO K, SUZUI Y, MASAKI T. Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0\/G1 cell cycle arrest. Anti-cancer drugs 31: 231-240, 2020. https:\/\/doi.org\/10.1097\/CAD.0000000000000870","DOI":"10.1097\/cad.0000000000000870"},{"key":"ref43","unstructured":"YANG L, MA B, SUN G, DONG CH, MA B: Antiproliferative and antiangiogenic effects of metformin on multidrug-resistant MCF-7 cells. Int J Clin Exp Med 11: 6776-6783, 2018."},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"ZAIDI S, GANDHI J, JOSHI G, SMITH NL, KHAN SA: The anticancer potential of metformin on prostate cancer. Prostate Cancer Prostatic Dis 22: 351-361, 2019. https:\/\/doi.org\/10.1038\/s41391-018-0085-2","DOI":"10.1038\/s41391-018-0085-2"},{"key":"ref45","unstructured":"ZHANG K, WANG J, WANG J, LUH F, LIU X, YANG L, LIU Y-R, SU L, YANG Y-CH SH, CHU P, YEN Y: LKB1 deficiency promotes proliferation and invasion of glioblastoma trough activation of mTOR and focal adhesion kinase signaling pathways. Am J Cancer Res 9: 1650-1663, 2019."},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"ZHAO J, MA Y, ZHANG Y, FU B, WU X, LI Q, CAI G, CHEN X, BAY X-Y: Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism. Cell Death Discov 5: 76, 2019. https:\/\/doi.org\/10.1038\/s41420-019-0156-8","DOI":"10.1038\/s41420-019-0156-8"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"ZI F, ZI H, LI Y, HE J, SHI Q, CAI Z: Metformin and cancer: An existing drug for cancer prevention and therapy (Review). Oncol Lett 15: 683-690, 2018. https:\/\/doi.org\/10.3892\/ol.2017.7412","DOI":"10.3892\/ol.2017.7412"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"ZONCU R, EFEYAN A, SABATINI DM: mTOR: form growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35, 2011. https:\/\/doi.org\/10.1038\/nrm3025","DOI":"10.1038\/nrm3025"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:15:00Z","timestamp":1630581300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2021\/70_501.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":49,"URL":"https:\/\/doi.org\/10.33549\/physiolres.934618","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,31]]}}}